The Coriell Institute for Medical Research is a global leader in biobanking, personalized medicine and stem cell biology. Recognized as one of the world’s leading biobanks, Coriell distributes biological samples and offers research and biobanking services to scientists in 85 countries and is the trusted steward of world-renowned collections for the National Institutes of Health, disease foundations and commercial clients. Through its long-running research study, the Coriell Personalized Medicine Collaborative, Coriell is investigating the utility of personal genomic information in patient care. The institute is also unlocking the promise of induced pluripotent stem cells and their potential in disease research and drug discovery. For more information, visit www.coriell.org.
Hackensack Meridian Health
Anthony A. delCampo, M.B.A., CLP, RTTP, Vice President, Office of Commercialization & Technology Ventures
The David and Alice Jurist Institute for Research
40 Prospect Avenue
Hackensack, NJ 07601
Hackensack Meridian Health is a leading not-for-profit healthcare organization that is the most comprehensive and truly integrated healthcare network in New Jersey, offering a complete range of medical services, innovative research and life-enhancing care. Hackensack Meridian Health is comprised of 13 hospitals, including two academic medical centers; Hackensack University Medical Center in Hackensack and Jersey Shore University Medical Center in Neptune, as well as, two children’s hospitals; Joseph M. Sanzari Children’s Hospital in Hackensack and the K. Hovnanian Children’s Hospital in Neptune. Hackensack Meridian Health also includes nine community hospitals, physician practices, more than120 ambulatory care centers, surgery centers, home health services, long-term care and assisted living communities, ambulance services, life-saving air medical transportation, fitness and wellness centers, rehabilitation centers and urgent care and after-hours centers. Hackensack Meridian Health has 28,000 team members, more than 6,000 physicians and is a distinguished leader in healthcare philanthropy, committed to the health and well-being of the communities it serves.
Institute for Life Science Entrepreneurship
Keith Bostian, CEO
1075 Morris Avenue
STEM Building, 5th Floor
Union, NJ 07083
The Institute for Life Science Entrepreneurship (ILSE) is a non-profit aiming to accelerate life science discoveries to improve human health, including new medicines, devices and transformative technologies. ILSE is both a technology accelerator and a science-driven research institute that works in partnership with affiliated academic and biomedical institutions across the region. ILSE Labs, the research business unit of ILSE, provides incubator space, consulting expertise via a network of global life-science experts and a network of R&D service organizations. ILSE’s ATCC Center for Translational Microbiology focuses on cutting-edge research in microbiome, advanced microbial genomics and clinical MDR antibiotic resistance.
New Jersey Institute of Technology
Office of Technology Development
Judith A. Sheft, Associate Vice President
Technology & Enterprise Development
349 East Building, University Heights
Newark, NJ 07102
Phone : 973-596-5825
Fax: 973- 596- 6056
One of the nation’s leading public technological universities, New Jersey Institute of Technology (NJIT) is a top-tier research university that prepares students to become leaders in the technology-dependent economy of the 21st century. NJIT’s multidisciplinary curriculum and computing-intensive approach to education provide technological proficiency, business acumen and leadership skills. NJIT is a global leader in such fields as solar research, nanotechnology, resilient design, tissue engineering and cybersecurity. NJIT ranks 5th among U.S. polytechnic universities in research expenditures, topping $121 million.
Launched in 2014 as an NJIT corporation, the New Jersey Innovation Institute (NJII) became a corporate entity that partners with industry and government to provide innovative and practical solutions for economic development, technical assistance, joint ventures and commercialization of technology in key industry sectors, including healthcare delivery systems, biopharmaceutical production, civil infrastructure, defense and homeland security and financial services.
Dean R. Edelman
Corporate Engagement & Foundation Relations
91 Prospect Avenue,
Princeton, NJ 08540
As a world-renowned research university, Princeton University seeks to achieve the highest levels of distinction in the discovery and transmission of knowledge and understanding. Through groundbreaking work in molecular and computational biology, chemistry, genomics, computer and data science, machine learning and artificial intelligence, research at Princeton advances understanding of human disease and wellness. For information on the many ways the life sciences industry can engage with Princeton, visit cefr.princeton.edu.
Anthony Lowman, Ph.D.
Dean of the College of Engineering
201 Mullica Hill Road
Glassboro, NJ 08028
As New Jersey’s newest public comprehensive research university, with both M.D. and D.O. degreegranting medical schools, Rowan University is a young, agile institution focused on applied research to solve real-world problems. Rowan is active in drug development, medical devices, diagnostics and digital health. Rowan is partnering with hospitals and industry to deliver customized solutions, spin out businesses in its South Jersey Technology Park and the future workforce for biopharmaceutical and healthcare companies. For more information, visit www.rowan.edu/home/research.
S. David Kimball, PhD, Associate Vice President
Office of Research Commercialization & Translational Sciences
33 Knightsbridge Road, 2nd Floor
Piscataway, NJ 08854
Established in 1766, Rutgers, The State University of New Jersey is America’s eighth oldest institution of higher learning, and one of the nation’s premier public research universities. Rutgers is a member of the Big Ten Conference and its academic counterpart, the Committee on Institutional Cooperation. For more information, please visit www.businessportal.rutgers.edu.
Stevens Institute of Technology
David Zimmerman, Ph.D., Director of Technology Commercialization
Office of Research, Innovation & Entrepreneurship
Building: Nicoll Laboratory
Stevens’ faculty and student researchers make significant scientific contributions to the pharmaceutical, biotechnology and medical device industries, to clinical research organizations and medical centers, as well as healthcare policy, delivery and management. Interdisciplinary teams capitalize on innovative developments in biology, chemistry, engineering, computer science, management, pharmaceutical manufacturing and new nano-scale and micro-scale technologies to translate laboratory innovation to patient care and well-being. In addition, Stevens’ researchers are developing innovative techniques in domains such as tissue engineering, computational drug discovery, biomaterial and biosensor development, and healthcare analytics.
Current projects at Stevens Institute of Technology include a search for cancer drugs targeting signaling pathways; searches for emerging therapies for traumatic lung injury and Parkinson’s disease; prosthetics and device development; analysis of ICU data to improve stroke-patient care; and improving disease models and research protocols for multiple myeloma, breast and prostate cancers and osteoporosis.
The College of New Jersey (TCNJ)
The College of New Jersey is a highly-selective, mid-sized college that leads the northern region of the country as a top-tier public institution. Located in central New Jersey, the colleges nationally-ranked STEM and business programs create graduates who contribute as innovative leaders to the growth and prosperity of the region s vibrant biotechnology cluster. TCNJ graduates are employed at many of the top biotech companies in and around New Jersey.
Albert Einstein College of Medicine
Offices of Biotechnology and Business Development
Richard Kosman, Director
1300 Morris Park Avenue
Room 908, Belfer Building
Bronx, NY 10461
The office of biotechnology serves as the technology transfer office of the college, facilitating the licensing of college technology to industry and research collaborations between industry and faculty. The office of business development serves to further enhance the value of the college’s research, clinical and intellectual property assets by proactively collaborating with the commercial, governmental, financial and entrepreneurial communities in novel initiatives.
Columbia Technology Ventures
Jerry Kokoshka, Ph.D., Senior Associate Director
51 Audubon Ave, 2nd Floor
New York, NY 10032
Columbia Technology Ventures (CTV) is the technology transfer office for Columbia University and a central location for many of the technology development initiatives, entrepreneurial activities, external industry collaborations and commercially oriented multidisciplinary technology innovations across the university. CTV’s core mission is to facilitate the transfer of inventions from academic research labs to the market for the benefit of society on a local, national and global basis. Each year, CTV manages more than 350 invention disclosures, 100 license deals and 20 new IP-backed start-ups; involving over 750 inventors across Columbia’s campuses. CTV currently has over 1,200 patent assets available for licensing across research fields, such as bio, IT, clean tech, devices, big data, nanotechnology, materials science and more.
Mt Sinai School of Medicine
Mt. Sinai Innovation Partners
Erik Lium, PhD, Vice President and Executive Director
770 Lexington Avenue, 14th Floor
New York, NY 10065
Phone: (212) 659-9680
Fax: (212) 348-4999
The Mt Sinai School of Medicine facilitates the transfer of discovery from the laboratory to the marketplace, linking Mount Sinai innovations with industry.
New York University
Office of Industrial Liaison
Abram Goldfinger, Executive Director
One Park Avenue, 6th Floor
New York, NY 10016
The Office of Industrial Liaison (OIL) at NYU promotes the commercial development of NYU technologies into products to benefit the public; while providing a return to the University to support its research, education and patient care missions. NYU has a strong track record of new venture creations and successfully commercializing promising discoveries. More than 30 products have come to market based on NYU technologies, including Remicade and Sutent diagnostics to help guide cancer and HIV therapy, and numerous medical devices, electronics and software technologies, and more than 120 new companies have been created. Over the past 10 years, NYU has ranked first among all U.S. universities in revenue from technology licensing, which is poured back into further research. We encourage companies, venture investors and entrepreneurs to contact us to explore how we can work together developing new technologies and creating new ventures to benefit the public and foster economic development.
Office of Technology Transfer
Kathleen A. Denis, Ph.D., Associate Vice President
502 Founders Hall
The Rockefeller University
1230 York Avenue, Box 138
New York, New York 10065
The Rockefeller University Office of Technology Transfer promotes and supports the research enterprise at the University by creating relationships with the private sector to develop, protect, transfer and commercialize research results for the public benefit.
Children’s Hospital of Philadelphia
Office of Technology Transfer
Ellen Purpus, PhD, Director
3615 Civic Center Boulevard
Philadelphia, PA 19104
The Office of Technology Transfer (OTT) serves as the liaison between Children’s Hospital’s basic and clinical research and the pharmaceutical and biotechnological industries. Its goal is to facilitate the development of products that advance medicine for the benefit of children and their families.
Office of Technology Commercialization
Robert McGrath, PhD, Senior Associate Vice Provost and Executive Director
The Left Bank
3180 Chestnut Street, Suite 104
Philadelphia, PA 19104
The Office of Technology Commercialization fulfills many roles at Drexel. First, it manages the intellectual property that is created at the University. Second, it serves as a bridge between Drexel’s faculty, staff and students with the private sector. The staff work with Drexel researchers to identify new technologies that may have commercial potential, works with intellectual property counsel to secure patent or copyright protection and negotiates license agreements with industry, investors and entrepreneurs to bring those technologies to market.
Pennsylvania State University
Office of Technology Management
Ronald J. “Ron” Huss, Associate Vice President
113 Technology Center Building
University Park, PA 16802
The Pennsylvania State University Office of Technology Management goal is to commercialize new products and services through the transfer of Penn State technologies to existing and start-up companies.
Office of Technology Development and Commercialization
Stephen G. Nappi, Associate Vice Provost
1938 Liacouras Walk, RM 211
Philadelphia, PA 19122-6027
The mission of the Temple University Office of Technology Development and Commercialization is to assist faculty, staff, and students to evaluate, protect, and realize the transfer of commercially viable intellectual property to the marketplace and contribute to knowledge-based economic development of the community and beyond.
University of Pennsylvania
Viviane Martin, Ph.D., Director, Perelman School of Medicine
Penn Center for Innovation
3160 Chestnut Street, Suite 200
Philadelphia, PA 19104
As America’s first university, the University of Pennsylvania has a history that dates back to 1740 and shares many ties with the colonial city of Philadelphia and the birth of our nation. Penn is one of the world’s most powerful research and teaching institutions, with a research budget of over $1 billion and more than 4,000 active faculty members. The Penn Center for Innovation (PCI) translates Penn discoveries and ideas into new products and businesses for the benefit of society by facilitating connections with the private sector. Whether the end result is a technology license, an R&D alliance, the formation of a new venture or an integrated combination of these activities, PCI serves as a dedicated one-stop shop for commercial partnering with Penn.
The Wistar Institute
Office of Business Development
Gayle Burstein-Teitelbaum, Ph.D., Associate, Licensing & Business Development
3601 Spruce Street
Philadelphia, PA 19104
The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent non-profit biomedical research institute in the country, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. Wistar’s mission includes a strong commitment to educate and train the next generation of scientists for promising new avenues of research; fostering the growth of a vital and essential life sciences workforce. Wistar has an entrepreneurial culture for commercialization of research discoveries to benefit public health. Through creative partnerships with academia, biotech and the pharmaceutical industry, the Institute is creating new opportunities that will accelerate the path of therapeutic advances from bench to bedside. Wistar’s pursuit of basic, fundamental science is the bedrock to understanding and curing disease. The Institute works to ensure that its research advances move from the laboratory to the clinic as quickly as possible.
To include your institution, please contact BioNJ@BioNJ.org.